 |
NARCAN Now |
|---|
| この情報はストアのものより古い可能性がございます。 | ||||
|
価格 | 無料 | ダウンロード |
|
|---|---|---|---|---|
| ｼﾞｬﾝﾙ | メディカル | |||
サイズ | 32.9MB | |||
| 開発者 | ADAPT Pharma Inc. | |||
| 順位 |
| |||
| ﾘﾘｰｽ日 | 2016-03-16 04:13:35 | 評価 | 評価が取得できませんでした。 | |
| 互換性 | iOS 9.0以降が必要です。 iPhone、iPad および iPod touch 対応。 | |||
NARCAN Now is the official app for NARCAN® (naloxone HCL) Nasal Spray. NARCAN Now is your tool for up-to-date product and safety information for NARCAN® Nasal Spray. With a simple to follow usage guide, pharmacy locater and training videos, you can ensure you are ready-to-use NARCAN Nasal Spray in the event of an opioid overdose emergency.
Indication and Important Safety Information
INDICATIONS
NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
NARCAN® Nasal Spray is not a substitute for emergency medical care.
IMPORTANT SAFETY INFORMATION
NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.
Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.
Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.
Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, increased heart rate (tachycardia), fever, runny nose, sneezing, goose bumps (piloerection), sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.
Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.
See Instructions for Use and full prescribing information in the use of this product.
To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
更新履歴
Bug fixes.
Indication and Important Safety Information
INDICATIONS
NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
NARCAN® Nasal Spray is not a substitute for emergency medical care.
IMPORTANT SAFETY INFORMATION
NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.
Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.
Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.
Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, increased heart rate (tachycardia), fever, runny nose, sneezing, goose bumps (piloerection), sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.
Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.
See Instructions for Use and full prescribing information in the use of this product.
To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
更新履歴
Bug fixes.
ブログパーツ第二弾を公開しました！ホームページでアプリの順位・価格・周辺ランキングをご紹介頂けます。
ブログパーツ第2弾！
アプリの周辺ランキングを表示するブログパーツです。価格・順位共に自動で最新情報に更新されるのでアプリの状態チェックにも最適です。
ランキング圏外の場合でも周辺ランキングの代わりに説明文を表示にするので安心です。
サンプルが気に入りましたら、下に表示されたHTMLタグをそのままページに貼り付けることでご利用頂けます。ただし、一般公開されているページでご使用頂かないと表示されませんのでご注意ください。
幅200px版
幅320px版
お気に入りのアプリをご紹介頂くためのブログパーツです。アプリの価格や順位表示は毎日自動更新♪
サンプルが気に入りましたら、下に表示されたHTMLタグをそのままページに貼り付けることでご利用頂けます。
※配信を停止させていただく可能性もございますので、タグの改変はご遠慮ください。
Now Loading...
「iPhone & iPad アプリランキング」は、最新かつ詳細なアプリ情報をご紹介しているサイトです。
お探しのアプリに出会えるように様々な切り口でページをご用意しております。
「メニュー」よりぜひアプリ探しにお役立て下さい。
Presents by $$308413110 スマホからのアクセスにはQRコードをご活用ください。 →
Now loading...